Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mendelian randomization study of sodium-glucose cotransporter 2 inhibitors in cardiac and renal diseases.

The Journal of international medical research - 1 Aug 2024

Chen Lei, Zuo Yongdi, He Manrong, Duo Lijin, Tang Wanxin

Abstract excerpt

OBJECTIVE: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) target the reabsorption of sodium and glucose in the kidney proximal tubules to reduce blood sugar levels. However, clinical randomized controlled trials on SGLT2i have yielded inconsistent results, necessitating further research into their efficacy and safety for specific cardiac and renal diseases. METHODS: "Sodium in urine" was selected as a...

Topics

Join the communities discussing this publication.

Diabetes Mellitus, Type 2
Genome-Wide Association Study
Glomerulonephritis
Heart Diseases
Kidney Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Mendelian Randomization Analysis

Nephrotic Syndrome

Source

Open in PubMed Open full text

Identifiers

PMID: 39216017
DOI: 10.1177/03000605241272639
PMCID: PMC11375684

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mendelian randomization study of sodium-glucose cotransporter 2 inhibitors in cardiac and renal diseases.PMID 39216017Read ↗

Pharmacological targets of SGLT2 inhibitors on IgA nephropathy and membranous nephropathy: a mendelian randomization studySemantic proximity Read ↗

Assessment of the effect of the SLC5A2 gene on eGFR: a Mendelian randomization study of drug targets for the nephroprotective effect of sodium-glucose cotransporter protein 2 inhibition.Semantic proximity Read ↗

Inhibition of sodium-glucose cotransporter-2 and liver-related complications in individuals with diabetes: a Mendelian randomization and population-based cohort study.Semantic proximity Read ↗

Long-Term Efficacy and Safety of GLP-1R Agonist and SGLT2 Inhibitor Therapy in the General Population: A 2x2 Factorial Mendelian Randomization StudySemantic proximity Read ↗

Type 2 Diabetes, Diabetes Genetic Score and Risk of Decreased Renal Function and Albuminuria: A Mendelian Randomization Study.Semantic proximity Read ↗

Using Mendelian randomization study to assess the renal effects of antihypertensive drugsSemantic proximity Read ↗

A bidirectional Mendelian randomization study supports causal effects of kidney function on blood pressureSemantic proximity Read ↗

Elucidating Genetic and Immunological Pathways Mediated by Sodium-Glucose Transporter 2 Inhibitors in Reducing Gout Risk: A Two-Step Mendelian Randomization Study.Semantic proximity Read ↗

Integrated approach of machine learning, Mendelian randomization and experimental validation for biomarker discovery in diabetic nephropathySemantic proximity Read ↗

Comprehensive Druggable Genome-Wide Mendelian Randomization Reveals Therapeutic Targets for Kidney DiseasesSemantic proximity Read ↗

Mendelian randomization reveals causal effects of kidney function on various biochemical parameters.Semantic proximity Read ↗

Diabetes mellitus, glycemic traits, SGLT2 inhibition, and risk of pulmonary arterial hypertension: A Mendelian randomization study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.